Focused on your Heart Health
Althera announces Roszet® approval by FDA
Althera Pharmaceuticals, a company focused on heart health, announces FDA approval of Roszet® (rosuvastatin and ezetimibe) tablets. By making this medicine available and affordable, we hope to improve long-term health of patients, including those with prior cardiovascular disease.
Please learn more about Roszet® at www.roszet.com.
Please read full Prescribing information at roszet.com/pi.
Founded in 2010, Althera develops innovative patient focused medicines to improve cardiovascular health.
Roszet (rosuvastatin and ezetimibe) tablets is expected to be available in pharmacies in United States in June 2021.
Althera’s Rosuvastatin/Ezetimibe is already approved and available to patients in more than 28 countries worldwide including all major European markets.
Althera’s second product Ezetimibe/Atorvastatin tablets (AL-310), is approved in both US and Europe, and is expected to be available to patients in 2021.